REG - BiVictriX Therapcts. - BiVictriX strengthens its patent portfolio

Bivictrix TherapeuticsAnnouncement

21/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220221:nRSU2007Ca&default-theme=true

RNS Number : 2007C  BiVictriX Therapeutics PLC  21 February 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

BiVictriX strengthens its patent portfolio with filing of four new patents

Alderley Park, 21 February 2022 - BiVictriX Therapeutics plc (AIM: BVX), an
emerging biotechnology company applying a novel approach to develop next
generation cancer therapies using insights derived from frontline clinical
experience, today announces that it has filed four new patent applications in
the UK related to several novel cancer-specific antigen pairs or
"fingerprints" across a range of oncology indications.

 

The new patent applications focus on three novel cancer-specific antigen
fingerprints that have been identified by the Company and can be used to
support the development of a pipeline of highly selective, cancer therapeutics
utilising the Company's proprietary Bi-Cygni® approach. This will further
strengthen BiVictriX's growing intellectual property portfolio and provide
opportunities to widen the application of the Company's Bi-Cygni® technology
across several solid tumour and haematological cancers, demonstrating the
broad utility of the approach. These filings are the next step in the
Company's strategy to broaden its patent portfolio both in the UK and
internationally.

 

BiVictriX's novel approach to cancer therapies relies on utilising its
proprietary library of cancer-specific antigen co-expression fingerprints, or
"twin antigens", which are uniquely expressed on a cancer. The Company's
pipeline of Bi-Cygni® therapeutics are designed to selectively target these
twin antigens which are present on tumour cells and largely absent from
healthy cells, enabling the development of a novel class of next-generation
anti-cancer therapies with potentially superior cancer selectivity and a
significantly reduced side-effect profile. This approach has the potential to
deliver better treatment outcomes for patients.

Tiffany Thorn, Chief Executive Officer of BiVictriX, commented: "We are
excited to be expanding our existing patent portfolio across a wider range of
cancer types that currently constitute areas of high unmet medical need,
demonstrating the broad utility of our innovative Bi-Cygni® platform. The new
patents, if approved, will provide broad protection for our pipeline assets,
allowing the development of several generations of cancer-selective Bi-Cygni®
therapeutics across a wide range of solid tumour and haematological cancers
that constitute areas of urgent unmet need. I look forward to providing
further updates regarding the application for these new patents as
appropriate."

 

The patent applications in BiVictriX's growing portfolio are wholly owned by
BiVictriX and, as such, are not subject to any licensing arrangements.

 

 

ENDS

 

   For more information, please contact:

BiVictriX Therapeutics plc
 Tiffany Thorn, Chief Executive Officer

 Iain Ross, Chairman                                Email: info@bivictrix.com (mailto:info@bivictrix.com)

 SP Angel Corporate Finance LLP (NOMAD and Broker)  Tel: +44 (0) 20 3470 0470
 David Hignell, Caroline Rowe (Corporate Finance)

 Vadim Alexandre, Rob Rees (Sales and Broking)

 Panmure Gordon (UK) Limited (Joint Broker)         Tel: +44 (0) 20 7886 2500
 Rupert Dearden/Freddy Crossley/Emma Earl

 Consilium Strategic Communications
 Mary-Jane Elliott, Genevieve Wilson, Alex Gunter   Tel: +44 (0) 20 3709 5700

                           Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is
focused on leveraging clinical experience to develop a class of highly
selective, next generation cancer therapeutics which exhibit superior potency,
whilst eliminating treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary
pipeline of Bi-Cygni® therapeutics which are designed to selectively target
antigen co-expression fingerprints, or "twin antigens", on tumour cells, which
are largely absent from healthy cells. Whereas this concept has been validated
in a clinical diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a therapeutic
setting.

 

BiVictriX has identified a diverse panel of novel cancer-specific "twin
antigens", across a broad range of cancer indications including Diffuse Large
B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic
Cell Neoplasm. The Company is using these novel "twin-antigens" to develop
more effective and safer therapeutics to target cancers that are expected to
constitute orphan indications and currently constitute areas of high unmet
medical need.

 

Find out more about BiVictriX online at www.bivictrix.com
(http://www.bivictrix.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKCBNDBKDNBD